Store in a cool, dry place & keep away from direct sunlight
This Study is only meant to provide early-stage indicative information to Lexaria about the possibility of enhancing the pharmacokinetic (PK) and pharmacodynamic performance of orally delivered GLP-1 drugs to assist in guiding the Lexaria team in additional investigations
The STEP-1 extension trial found that participants regained approximately two-thirds of their lost weight within one year after stopping GLP-1 treatment.Additional research published in BMC Medicine (2025) observed that weight regain can begin as early as eight weeks after discontinuation, with rebound effects continuing for several months
LY3437943 significantly decreased plasma glucose (blood sugar), HbA1c, and body weight in a dose-dependent manner
"Basically, the pharmacy almost laughed at me
The effect is transient, and appears not to cause damage, probably because cell turnover in the gastric mucosa is rapidas observed following ethanol absorption in the stomach (263265)
